NEW YORK, Nov. 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of InfuSystem Holdings, Inc. (“InfuSystem” or “the Company”) (NYSE MKT:INFU) between May 12, 2015 and November 7, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. To get more information go to:
http://www.zlk.com/pslra/infusystem-holdings
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period InfuSystem made false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective internal control over financial reporting; (2) InfuSystem’s financial statements dating back to the beginning of 2015 overstated the estimated accounts receivable collections, which in turn overstated revenues and pre-tax income by a corresponding amount; (3) InfuSystem’s financial statements dating back to the beginning of 2015 could no longer be relied upon; and (4) as a result of the foregoing, InfuSystem’s financial statements were materially false and misleading at all relevant times.
If you suffered a loss in InfuSystem you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Anta Sports Expands Global Footprint With Strategic Puma Stake
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



